Zheng Quan Shi Bao Wang·2024-12-20 00:15Group 1 - The core viewpoint is that the reform policies in the pharmaceutical sector are becoming normalized, with a focus on the establishment of a diversified payment system in the healthcare sector by 2025 [1] - The upcoming reforms in the healthcare sector will include salary systems and hierarchical diagnosis and treatment, which are expected to align with overall expectations [1] - The Chinese pharmaceutical industry is gradually gaining international recognition, with marginal improvements expected in certain sub-sectors and the beginning of industry consolidation [1] Group 2 - It is recommended to focus on new growth areas such as innovation, international expansion, and marginal changes, as well as opportunities arising from industry consolidation [2]